Huabei Pharmaceutical Shares Surge Over 24 Percent Across Three Sessions

Huabei Pharmaceutical shares surged over 24 percent across three trading sessions ending October 9, 2026, driven by market interest in plague-related pharmaceutical concepts. bjnews.com.cn reported that the company issued an abnormal stock trading fluctuation announcement stating its injection-grade streptomycin sulfate is indicated for plague treatment, though its small revenue scale will not materially impact financial performance. financial.ifeng.com noted that the stock hit consecutive daily limit-ups on October 8 and October 9, closing at 6.03 yuan per share on the final day, while cfn.net.cn confirmed the company’s valuation stands at an 83.84 times rolling price-to-earnings ratio compared to an industry average of 26.71.

Stock Market Volatility and Company Disclosures

Market reaction extended beyond Huabei Pharmaceutical to encompass several other pharmaceutical and medical supply companies. financial.ifeng.com reported that A股 anti-plague and flu concepts experienced sharp buying activity following reports from Russia, with companies such as Zhonghong Medical, Rundu Shares, and Lukang Medicine seeing significant intraday movements. Zhonghong Medical hit a 20 percent daily limit-up on October 9 to close at 23.36 yuan per share, driven by trading interest in its nitrile protective gloves exported to international markets.

Representatives from multiple firms sought to clarify their direct business exposure amid the speculative surge. financial.ifeng.com reported that Rundu Shares stated its newly approved moxifloxacin hydrochloride tablets list plague treatment and prevention among indications, but sales figures have not been broken out in current financial reports because revenue contribution remains minor. Zhijiang Bio responded to investor inquiries on October 9 by stating it maintains seven pathogen detection kits for rodent carriers and automated negative-pressure testing equipment, though bjnews.com.cn observed its shares experienced a brief rise before declining to close at 19.19 yuan per share.

Epidemiological Investigation in Russia

Official Russian authorities subsequently disputed claims of an active plague outbreak or secondary transmission. bjnews.com.cn cited a news.cn dispatch stating that the Russian Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing issued an update on October 7 declaring the epidemiological situation in Irkutsk Oblast stable and free of health risks. The agency reported that over 90 percent of close contacts completed medical observation without health abnormalities, and nearly 5,000 laboratory tests detected no dangerous pathogens. news.china.com added that local authorities began lifting preventive measures in Irkutsk city as health monitoring concluded.

Therapeutic Guidelines and Market Valuations

Medical guidance issued by regulatory bodies outlines specific treatment protocols for plague, utilizing standard antibiotics rather than specialized mass vaccination. news.china.com noted that China’s National Health Commission 2023 diagnosis and treatment guidelines identify streptomycin as the primary drug for treating various forms of plague, while ciprofloxacin, levofloxacin, and moxifloxacin serve as alternative or supplemental treatments.

financial.ifeng.com reported that clinical specialists emphasized that streptomycin clinical usage remains strictly monitored and limited during normal periods, primarily serving as a designated reserve medication managed through disease control channels rather than retail pharmacy inventory. financial.ifeng.com highlighted that Huabei Pharmaceutical warned investors about its elevated valuation, pointing out that its rolling price-to-earnings ratio of 83.84 greatly exceeds the pharmaceutical manufacturing industry average of 26.71.